Aerovate Therapeutics
Yahoo Finance • 9 days ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, AVTE, HEES, AMPY on Behalf of Shareholders
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story
Yahoo Finance • 11 days ago
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AMPY, HEES, AVTE, TGI to Act Now
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Service... Full story
Yahoo Finance • 19 days ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
NEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story
Yahoo Finance • 25 days ago
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NHHS, KVAC, AMPS, AVTE
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report.... Full story
Yahoo Finance • last month
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, GB on Behalf of Shareholders
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story
Yahoo Finance • last month
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NVRO, LGTY, AVTE, PLYA
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. W... Full story
Yahoo Finance • 2 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IVAC, AVTE, QTRX on Behalf of Shareholders
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story
Yahoo Finance • 2 months ago
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MHLD, IPG, AVTE on Behalf of Shareholders
NEW YORK, Jan. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story
Yahoo Finance • 2 months ago
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - IPG, VTS, AVTE, MHLD
NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. W... Full story
Yahoo Finance • last year
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVT... Full story
Yahoo Finance • last year
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonar... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonar... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonar... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH)More than 100 sites activated in 20 countries with the pace of enrol... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expanded intellectual property portfolio with four issued patents in 2022 Management team strengthened and expan... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmona... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonar... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonar... Full story
Yahoo Finance • 2 years ago
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
WALTHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today presents the design of IMPAHCT (Inhaled iMatinib for Pulmonary Arterial Hypertension Clinical Trial; AV-101-002), a Phase 2b/Phase 3 trial... Full story
Yahoo Finance • 3 years ago
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonar... Full story
